Full-Time

Frontend Software Engineer

Confirmed live in the last 24 hours

Deadline 5/28/25
AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

No salary listed

Mid, Senior

Sant Cugat del Vallès, Barcelona, Spain

On-site commitment of three days a week.

Category
Frontend Engineering
Software Engineering
Required Skills
React.js
Redux.js
TypeScript
Axios
REST APIs
Requirements
  • Proficiency in React, React Router, State management using Redux or similar.
  • Experience working with Axios or similar.
  • Experience building microfrontends.
  • Restful API development and integration.
  • Solid understanding of HTML5 and CSS3.
  • Understanding of React performance techniques (memoization, lazy loading) and browser tools for debugging.
  • Experience with Typescript.
  • Strong understanding of software development principles, such as object-oriented programming and Agile methodologies.
  • 3 to 5 years of professional experience in software development.
Responsibilities
  • Building and maintaining frontend interfaces for our applications.
  • Writing reusable, modular React components.
  • Collaborating with other engineers, product owners, and stakeholders to refine features and ensure they deliver outcomes.
  • Implementing responsive designs.
  • Troubleshooting, diagnosing, and resolving bugs and performance issues.
  • Participating in Agile ceremonies, such as daily stand-ups and sprint planning.
Desired Qualifications
  • Experience designing solutions for complex projects within large organizations.
  • Familiarity with common frontend libraries.
  • Experience with CI/CD tools, such as Azure DevOps or GitHub Actions.
  • Experience with Automated UI Testing, such as Selenium.

AstraZeneca develops and sells prescription medicines, focusing on three main areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Their products are created through extensive research and development, which includes clinical trials and regulatory approvals. Unlike many competitors, AstraZeneca emphasizes collaboration through its Open Innovation program and the A.Catalyst Network, which connects health innovation hubs worldwide. The company's goal is to advance healthcare by providing effective treatments for serious diseases.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EsoBiotec boosts AstraZeneca's cell therapy capabilities for cancer treatment.
  • New facilities in Rockville and Wuxi expand production capacity and market reach.
  • Positive DESTINY-Breast11 trial results strengthen AstraZeneca's oncology portfolio.

What critics are saying

  • Increased competition in oncology may impact AstraZeneca's market share.
  • Integrating EsoBiotec's technology could lead to operational challenges and costs.
  • Regulatory scrutiny on new cell therapies may delay product launches.

What makes AstraZeneca unique

  • AstraZeneca leads in oncology with a robust pipeline and innovative treatments.
  • The company excels in strategic collaborations, enhancing research and product development.
  • AstraZeneca's A.Catalyst Network fosters global health innovation and scientific advancements.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

HC Data
May 21st, 2025
AstraZeneca Marks Seventh Consecutive Year of Plenary Data at ASCO, Advancing Breast and Gastric Cancer Care

AstraZeneca will present new data from over 80 abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 - June 3), underscoring its leadership in oncology through a diverse and robust pipeline.

Cision
May 21st, 2025
Director Declaration

21 May 2025Director DeclarationAstraZeneca PLC (the Company) today announced that Pascal Soriot, Chief Executive Officer of the Company, has been appointed a director of Agilent Technologies Inc. with effect from 21 May 2025.This announcement is made pursuant to Listing Rule 6.4.9 (2).AstraZenecaAstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZenecaContactsFor details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.Matthew BowdenCompany SecretaryAstraZeneca PLCThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom

Clinical Trials Arena
May 20th, 2025
ATS 2025: Tozorakimab's safety reinforced with positive results from FRONTIER studies

On 18 May at the 2025 American Thoracic Society (ATS) International Conference, AstraZeneca presented results on its interleukin-33 (IL-33) inhibitor, tozorakimab, from its FRONTIER programmes, which are a series of four Phase II clinical trials.

Cision
May 20th, 2025
Acquisition Of Esobiotec Completed

20 May 2025 Acquisition of EsoBiotec completed AstraZeneca today announced the successful completion of the acquisition (https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-to-acquire-esobiotec.html) of EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune system to attack cancers and could offer many more patients access to transformative cell therapy treatments delivered in just minutes rather than the current

BioBuzz
May 12th, 2025
AstraZeneca Opens New Cell Therapy Manufacturing Facility in Rockville, Signaling Major Boost to Maryland's Biotech Economy

In collaboration with general contractor CRB, a life sciences design and construction firm, AstraZeneca embedded operational redundancy and agility into every layer of the facility's architecture.